KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Capital Expenditures: 2009-2024

Historic Capital Expenditures for Pacira BioSciences (PCRX) over the last 16 years, with Dec 2024 value amounting to $10.6 million.

  • Pacira BioSciences' Capital Expenditures fell 5.43% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.2 million, marking a year-over-year increase of 67.05%. This contributed to the annual value of $10.6 million for FY2024, which is 29.85% down from last year.
  • Per Pacira BioSciences' latest filing, its Capital Expenditures stood at $10.6 million for FY2024, which was down 29.85% from $15.2 million recorded in FY2023.
  • Pacira BioSciences' 5-year Capital Expenditures high stood at $45.9 million for FY2021, and its period low was $10.6 million during FY2024.
  • Over the past 3 years, Pacira BioSciences' median Capital Expenditures value was $15.2 million (recorded in 2023), while the average stood at $18.6 million.
  • Per our database at Business Quant, Pacira BioSciences' Capital Expenditures soared by 272.09% in 2020 and then plummeted by 49.59% in 2023.
  • Over the past 5 years, Pacira BioSciences' Capital Expenditures (Yearly) stood at $37.8 million in 2020, then rose by 21.34% to $45.9 million in 2021, then tumbled by 34.43% to $30.1 million in 2022, then crashed by 49.59% to $15.2 million in 2023, then decreased by 29.85% to $10.6 million in 2024.